Form 4: Celldex CFO Exercises Stock Options
Insider Transaction Report
Celldex Therapeutics' SVP and CFO, Samuel Bates Martin, exercised stock options to acquire 4,817 shares of common stock.
Summary
- Samuel Bates Martin, SVP and CFO of Celldex Therapeutics, Inc. (CLDX), acquired 4,817 shares of common stock on January 2, 2026.
- The acquisition was a result of exercising an Incentive Stock Option (Right to Buy) at an exercise price of $10.38 per share.
- Following this transaction, Martin directly beneficially owns 32,942 shares of Celldex Therapeutics common stock.
- The exercised option was fully vested as of June 18, 2024, and had an expiration date of June 18, 2030.
- After the exercise, Martin continues to beneficially own 58,815 derivative securities (Incentive Stock Options).
Sentiment
Score: 7
Explanation: The exercise of stock options by a senior executive to acquire common stock is generally viewed as a neutral to slightly positive signal, indicating confidence or routine equity management. It's a standard part of executive compensation.
Positives
- An insider, the SVP and CFO, increased their direct beneficial ownership of common stock by 4,817 shares, which can signal confidence in the company's future prospects.
Future Outlook
NA
Industry Context
This is a routine insider transaction and does not provide specific insights into broader industry trends or competitive landscape. It reflects an individual executive's equity management.
Stakeholder Impact
- Shareholders may view the increase in insider ownership as a positive sign of management's alignment with shareholder interests, though the impact is minor given the routine nature of the transaction.
Key Dates
| Date | Description |
|---|---|
| 06/18/2024 | Date the Incentive Stock Option became fully vested. |
| 01/02/2026 | Date of the transaction where stock options were exercised and common stock was acquired. |
| 01/06/2026 | Date the Form 4 was filed. |
| 06/18/2030 | Expiration date of the Incentive Stock Option. |
Recommendation
holdThis Form 4 filing details a routine insider transaction where the CFO exercised stock options. While the acquisition of shares by an insider can be a positive signal, this event alone is not significant enough to warrant a change in investment recommendation. Investors should consider broader company fundamentals and market conditions.
Keywords
Celldex Therapeutics, CLDX, Form 4, Insider Transaction, Stock Options, Equity Acquisition, CFO, Samuel Bates Martin
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.